This statistic displays the average time of non-oncology orphan medicines gaining marketing authorization and patient access in European countries as of January 5, 2024. According to the data, Germany had an average time of 107 days between authorization and access for non-oncology orphan medicines (for drugs launched from 2019 to 2022), compared to around 960 days in Lithuania.
Average time between marketing approval and patient access for non-oncology orphan drugs in Europe as of 2024, by country
(in days)
Data collected is for drugs launched from 2019 to 2022. In most countries, availability equates to granting of access to the reimbursement list, except in DK, FI, NO, SE some hospital products are not covered by the general reimbursement scheme. The time to availability (formerly known as length of delay) is the days between EMA marketing authorization and the date of availability to patients.Â
* These countries did not complete a full dataset and therefore availability may be unrepresentative. ** The source mentions that it does not consider France's system of temporary authorization for some products, which means this time will be higher than in reality. *** MHRA’s Early Access to Medicines Scheme provides access before marketing authorization but is not included within this analysis, and would reduce the overall days for a small subset of medicines.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
IQVIA, & EFPIA. (June 25, 2024). Average time between marketing approval and patient access for non-oncology orphan drugs in Europe as of 2024, by country (in days) [Graph]. In Statista. Retrieved November 22, 2024, from https://www.statista.com/statistics/1248715/europe-time-between-non-oncology-orphan-drugs-authorization-and-access/
IQVIA, und EFPIA. "Average time between marketing approval and patient access for non-oncology orphan drugs in Europe as of 2024, by country (in days)." Chart. June 25, 2024. Statista. Accessed November 22, 2024. https://www.statista.com/statistics/1248715/europe-time-between-non-oncology-orphan-drugs-authorization-and-access/
IQVIA, EFPIA. (2024). Average time between marketing approval and patient access for non-oncology orphan drugs in Europe as of 2024, by country (in days). Statista. Statista Inc.. Accessed: November 22, 2024. https://www.statista.com/statistics/1248715/europe-time-between-non-oncology-orphan-drugs-authorization-and-access/
IQVIA, and EFPIA. "Average Time between Marketing Approval and Patient Access for Non-oncology Orphan Drugs in Europe as of 2024, by Country (in Days)." Statista, Statista Inc., 25 Jun 2024, https://www.statista.com/statistics/1248715/europe-time-between-non-oncology-orphan-drugs-authorization-and-access/
IQVIA & EFPIA, Average time between marketing approval and patient access for non-oncology orphan drugs in Europe as of 2024, by country (in days) Statista, https://www.statista.com/statistics/1248715/europe-time-between-non-oncology-orphan-drugs-authorization-and-access/ (last visited November 22, 2024)
Average time between marketing approval and patient access for non-oncology orphan drugs in Europe as of 2024, by country (in days) [Graph], IQVIA, & EFPIA, June 25, 2024. [Online]. Available: https://www.statista.com/statistics/1248715/europe-time-between-non-oncology-orphan-drugs-authorization-and-access/
